ClearPoint Neuro (CLPT) Stock Forecast, Price Target & Predictions
CLPT Stock Forecast
ClearPoint Neuro stock forecast is as follows: an average price target of $12.00 (represents a -5.81% downside from CLPT’s last price of $12.74) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CLPT Price Target
The average price target for ClearPoint Neuro (CLPT) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $9.00. This represents a potential -5.81% downside from CLPT's last price of $12.74.
CLPT Analyst Ratings
According to 1 Wall Street analysts, ClearPoint Neuro's rating consensus is 'Buy'. The analyst rating breakdown for CLPT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ClearPoint Neuro Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Frank Takkinen | Loop Capital Markets | $15.00 | $12.60 | 19.00% | 17.74% |
| Mar 13, 2024 | Mathew Blackman | Stifel Nicolaus | $9.00 | $7.17 | 25.52% | -29.36% |
The latest ClearPoint Neuro stock forecast, released on Aug 27, 2024 by Frank Takkinen from Loop Capital Markets, set a price target of $15.00, which represents a 19.00% increase from the stock price at the time of the forecast ($12.60), and a 17.74% increase from CLPT last price ($12.74).
ClearPoint Neuro Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $15.00 | $12.00 |
| Last Closing Price | $12.74 | $12.74 | $12.74 |
| Upside/Downside | -100.00% | 17.74% | -5.81% |
In the current month, the average price target of ClearPoint Neuro stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ClearPoint Neuro's last price of $12.74. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Lake Street | Buy | Buy | Hold |
ClearPoint Neuro's last stock rating was published by Lake Street on Aug 27, 2024. The company gave CLPT a "Buy" rating, the same as its previous rate.
ClearPoint Neuro Financial Forecast
ClearPoint Neuro Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 16 | Mar 15 | Jun 14 | Mar 13 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $6.81M | $5.76M | $5.95M | $5.43M | $5.17M | $5.15M | $5.20M | $5.03M | $4.28M | $4.57M | $3.41M | $4.03M | $3.72M | $3.52M | $2.48M | $3.12M | $1.39M | $1.01M | $1.19M | $1.26M | $1.13M |
| Avg Forecast | $9.60M | $9.30M | $8.90M | $8.60M | $8.00M | $7.77M | $7.33M | $6.99M | $6.53M | $6.73M | $5.90M | $5.00M | $5.20M | $5.40M | $5.08M | $4.18M | $4.30M | $4.00M | $3.69M | $3.27M | $3.24M | $2.47M | $1.88M | $3.54M | $27.98K | $27.66K | $39.13K | $1.26M | $2.26M |
| High Forecast | $9.60M | $9.30M | $8.90M | $8.60M | $8.00M | $7.80M | $7.33M | $6.99M | $6.94M | $6.73M | $5.90M | $5.00M | $5.20M | $5.40M | $5.08M | $4.18M | $4.30M | $4.00M | $3.69M | $3.27M | $3.24M | $2.47M | $1.88M | $3.54M | $33.58K | $33.20K | $46.96K | $1.52M | $2.72M |
| Low Forecast | $9.60M | $9.30M | $8.90M | $8.60M | $8.00M | $7.74M | $7.33M | $6.99M | $6.12M | $6.73M | $5.90M | $5.00M | $5.20M | $5.40M | $5.08M | $4.18M | $4.30M | $4.00M | $3.69M | $3.27M | $3.24M | $2.47M | $1.88M | $3.54M | $22.38K | $22.13K | $31.31K | $1.01M | $1.81M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 20 | 17 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | 1.04% | 0.86% | 1.01% | 1.09% | 0.99% | 0.95% | 1.02% | 1.20% | 1.00% | 1.14% | 0.93% | 1.23% | 1.15% | 1.43% | 1.32% | 0.88% | 49.82% | 36.53% | 30.38% | 1.00% | 0.50% |
ClearPoint Neuro's average Quarter revenue forecast for Mar 24 based on 1 analysts is $6.99M, with a low forecast of $6.99M, and a high forecast of $6.99M. CLPT's average Quarter revenue forecast represents a 2.70% increase compared to the company's last Quarter revenue of $6.81M (Dec 23).
ClearPoint Neuro EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 16 | Mar 15 | Jun 14 | Mar 13 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 20 | 17 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $-4.28M | $-4.90M | $-7.13M | $-5.44M | $-4.32M | $-3.79M | $-3.98M | $-3.63M | $-3.94M | $-3.69M | $-3.46M | $-2.19M | $-1.21M | $-1.23M | $-1.41M | $-1.18M | $-1.65M | $-3.55M | $-1.20M | $-729.75K | $-892.51K |
| Avg Forecast | $-6.10M | $-5.91M | $-5.65M | $-5.46M | $-5.08M | $-4.93M | $-4.66M | $-4.44M | $-4.15M | $-4.27M | $-3.75M | $-3.18M | $-3.30M | $-3.43M | $-3.23M | $-4.18M | $-2.73M | $-2.54M | $-2.34M | $-2.21M | $-2.06M | $-1.57M | $-1.19M | $-1.48M | $-1.65M | $-2.80M | $-1.49M | $-603.49K | $-1.20M |
| High Forecast | $-6.10M | $-5.91M | $-5.65M | $-5.46M | $-5.08M | $-4.91M | $-4.66M | $-4.44M | $-3.89M | $-4.27M | $-3.75M | $-3.18M | $-3.30M | $-3.43M | $-3.23M | $-3.34M | $-2.73M | $-2.54M | $-2.34M | $-1.76M | $-2.06M | $-1.57M | $-1.19M | $-1.18M | $-1.32M | $-2.24M | $-1.20M | $-482.79K | $-963.91K |
| Low Forecast | $-6.10M | $-5.91M | $-5.65M | $-5.46M | $-5.08M | $-4.95M | $-4.66M | $-4.44M | $-4.41M | $-4.27M | $-3.75M | $-3.18M | $-3.30M | $-3.43M | $-3.23M | $-5.01M | $-2.73M | $-2.54M | $-2.34M | $-2.65M | $-2.06M | $-1.57M | $-1.19M | $-1.78M | $-1.98M | $-3.36M | $-1.79M | $-724.19K | $-1.45M |
| Surprise % | - | - | - | - | - | - | - | - | 1.03% | 1.15% | 1.90% | 1.71% | 1.31% | 1.11% | 1.23% | 0.87% | 1.44% | 1.45% | 1.48% | 0.99% | 0.59% | 0.78% | 1.18% | 0.80% | 1.00% | 1.27% | 0.80% | 1.21% | 0.74% |
undefined analysts predict CLPT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ClearPoint Neuro's previous annual EBITDA (undefined) of $NaN.
ClearPoint Neuro Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 16 | Mar 15 | Jun 14 | Mar 13 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 20 | 17 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $-4.62M | $-4.81M | $-7.05M | $-5.39M | $-4.30M | $-3.78M | $-4.40M | $-4.05M | $-4.31M | $-3.98M | $-3.74M | $-2.54M | $-1.58M | $-1.48M | $-1.66M | $-2.05M | $-2.04M | $-3.95M | $-1.59M | $-950.00K | $-1.07M |
| Avg Forecast | $-4.14M | $-4.05M | $-3.97M | $-4.01M | $-4.77M | $-4.76M | $-5.40M | $-5.22M | $-5.59M | $-6.87M | $-5.22M | $-5.22M | $-5.49M | $-5.22M | $-5.09M | $-4.55M | $-5.22M | $-4.39M | $-3.71M | $-2.72M | $-3.57M | $-3.85M | $-4.39M | $-2.63M | $-2.04M | $-3.11M | $-1.99M | $-823.75K | $-1.45M |
| High Forecast | $-4.14M | $-4.05M | $-3.97M | $-4.01M | $-4.77M | $-3.92M | $-5.40M | $-5.22M | $-4.82M | $-6.87M | $-5.22M | $-5.22M | $-5.49M | $-5.22M | $-5.09M | $-3.64M | $-5.22M | $-4.39M | $-3.71M | $-2.18M | $-3.57M | $-3.85M | $-4.39M | $-2.10M | $-1.64M | $-2.49M | $-1.59M | $-659.00K | $-1.16M |
| Low Forecast | $-4.14M | $-4.05M | $-3.97M | $-4.01M | $-4.77M | $-5.32M | $-5.40M | $-5.22M | $-6.09M | $-6.87M | $-5.22M | $-5.22M | $-5.49M | $-5.22M | $-5.09M | $-5.46M | $-5.22M | $-4.39M | $-3.71M | $-3.26M | $-3.57M | $-3.85M | $-4.39M | $-3.15M | $-2.45M | $-3.73M | $-2.39M | $-988.50K | $-1.74M |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% | 0.70% | 1.35% | 1.03% | 0.78% | 0.72% | 0.87% | 0.89% | 0.83% | 0.91% | 1.01% | 0.93% | 0.44% | 0.39% | 0.38% | 0.78% | 1.00% | 1.27% | 0.80% | 1.15% | 0.74% |
ClearPoint Neuro's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CLPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ClearPoint Neuro SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 16 | Mar 15 | Jun 14 | Mar 13 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 20 | 17 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $6.07M | $5.74M | $6.65M | $5.89M | $4.16M | $5.05M | $5.18M | $4.58M | $4.54M | $4.26M | $3.57M | $3.23M | $2.72M | $2.86M | $2.49M | $2.58M | $1.97M | $2.29M | $1.93M | $1.63M | $1.44M |
| Avg Forecast | $8.72M | $8.44M | $8.08M | $7.81M | $7.26M | $7.05M | $6.66M | $6.35M | $5.93M | $6.11M | $5.36M | $4.54M | $4.72M | $4.90M | $4.61M | $3.80M | $3.90M | $3.63M | $3.35M | $2.97M | $2.94M | $2.24M | $1.70M | $3.29M | $25.40K | $25.11K | $35.53K | $1.15M | $1.95M |
| High Forecast | $8.72M | $8.44M | $8.08M | $7.81M | $7.26M | $7.08M | $6.66M | $6.35M | $6.30M | $6.11M | $5.36M | $4.54M | $4.72M | $4.90M | $4.61M | $3.80M | $3.90M | $3.63M | $3.35M | $2.97M | $2.94M | $2.24M | $1.70M | $3.95M | $30.48K | $30.14K | $42.63K | $1.38M | $2.34M |
| Low Forecast | $8.72M | $8.44M | $8.08M | $7.81M | $7.26M | $7.02M | $6.66M | $6.35M | $5.56M | $6.11M | $5.36M | $4.54M | $4.72M | $4.90M | $4.61M | $3.80M | $3.90M | $3.63M | $3.35M | $2.97M | $2.94M | $2.24M | $1.70M | $2.63M | $20.32K | $20.09K | $28.42K | $918.18K | $1.56M |
| Surprise % | - | - | - | - | - | - | - | - | 1.02% | 0.94% | 1.24% | 1.30% | 0.88% | 1.03% | 1.12% | 1.21% | 1.16% | 1.17% | 1.07% | 1.09% | 0.93% | 1.28% | 1.46% | 0.78% | 77.72% | 91.13% | 54.30% | 1.42% | 0.74% |
ClearPoint Neuro's average Quarter SG&A projection for Mar 24 is $6.35M, based on 1 Wall Street analysts, with a range of $6.35M to $6.35M. The forecast indicates a 4.65% rise compared to CLPT last annual SG&A of $6.07M (Dec 23).
ClearPoint Neuro EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Mar 16 | Mar 15 | Jun 14 | Mar 13 | Sep 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 20 | 17 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | $-0.19 | $-0.20 | $-0.00 | $-0.22 | $-0.18 | $-0.15 | $-0.18 | $-0.17 | $-0.19 | $-0.18 | $-0.17 | $-0.13 | $-0.09 | $-0.09 | $-0.11 | $-0.13 | $-0.80 | $-2.00 | $-1.20 | $-0.80 | $-0.80 |
| Avg Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.15 | $-0.17 | $-0.17 | $-0.20 | $-0.19 | $-0.20 | $-0.25 | $-0.19 | $-0.19 | $-0.20 | $-0.19 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.14 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.18 | $-0.80 | $-0.95 | $-2.00 | $-0.80 | $-2.16 |
| High Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.15 | $-0.17 | $-0.14 | $-0.20 | $-0.19 | $-0.18 | $-0.25 | $-0.19 | $-0.19 | $-0.20 | $-0.19 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.14 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.18 | $-0.64 | $-0.76 | $-1.60 | $-0.64 | $-1.73 |
| Low Forecast | $-0.15 | $-0.15 | $-0.14 | $-0.15 | $-0.17 | $-0.19 | $-0.20 | $-0.19 | $-0.22 | $-0.25 | $-0.19 | $-0.19 | $-0.20 | $-0.19 | $-0.19 | $-0.20 | $-0.19 | $-0.16 | $-0.14 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.18 | $-0.96 | $-1.13 | $-2.40 | $-0.96 | $-2.59 |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | 0.80% | 0.00% | 1.16% | 0.90% | 0.79% | 0.97% | 0.85% | 1.00% | 1.13% | 1.26% | 0.90% | 0.69% | 0.64% | 0.69% | 0.72% | 1.00% | 2.11% | 0.60% | 1.00% | 0.37% |
According to undefined Wall Street analysts, ClearPoint Neuro's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CLPT previous annual EPS of $NaN (undefined).
ClearPoint Neuro Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OM | Outset Medical | $0.62 | $11.00 | 1674.19% | Buy |
| CTSO | Cytosorbents | $0.87 | $9.00 | 934.48% | - |
| APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
| TELA | TELA Bio | $2.85 | $12.50 | 338.60% | Buy |
| INGN | Inogen | $9.03 | $26.00 | 187.93% | Buy |
| SGHT | Sight Sciences | $4.66 | $10.25 | 119.96% | Hold |
| NPCE | NeuroPace | $6.37 | $12.88 | 102.20% | Buy |
| LUNG | Pulmonx | $7.12 | $11.93 | 67.56% | Buy |
| LIVN | LivaNova | $49.01 | $70.50 | 43.85% | Buy |
| KIDS | OrthoPediatrics | $28.74 | $39.60 | 37.79% | Buy |
| NARI | Inari Medical | $48.93 | $66.11 | 35.11% | Buy |
| INSP | Inspire Medical Systems | $192.71 | $238.00 | 23.50% | Buy |
| SRDX | Surmodics | $37.57 | $39.50 | 5.14% | Buy |
| CLPT | ClearPoint Neuro | $12.74 | $12.00 | -5.81% | Buy |
| RCEL | AVITA Medical | $11.17 | $9.00 | -19.43% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
CLPT Forecast FAQ
Is ClearPoint Neuro a good buy?
Yes, according to 1 Wall Street analysts, ClearPoint Neuro (CLPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CLPT's total ratings.
What is CLPT's price target?
ClearPoint Neuro (CLPT) average price target is $12 with a range of $9 to $15, implying a -5.81% from its last price of $12.74. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ClearPoint Neuro stock go up soon?
According to Wall Street analysts' prediction for CLPT stock, the company can go down by -5.81% (from the last price of $12.74 to the average price target of $12), up by 17.74% based on the highest stock price target, and down by -29.36% based on the lowest stock price target.
Can ClearPoint Neuro stock reach $20?
CLPT's average twelve months analyst stock price target of $12 does not support the claim that ClearPoint Neuro can reach $20 in the near future.
What are ClearPoint Neuro's analysts' financial forecasts?
ClearPoint Neuro's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $30.09M (high $30.12M, low $30.06M), average EBITDA is $-19.112M (high $-19.094M, low $-19.131M), average net income is $-20.154M (high $-19.314M, low $-20.713M), average SG&A $27.32M (high $27.35M, low $27.29M), and average EPS is $-0.734 (high $-0.703, low $-0.754). CLPT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $36.4M (high $36.4M, low $36.4M), average EBITDA is $-23.117M (high $-23.117M, low $-23.117M), average net income is $-16.173M (high $-16.173M, low $-16.173M), average SG&A $33.05M (high $33.05M, low $33.05M), and average EPS is $-0.589 (high $-0.589, low $-0.589).
Did the CLPT's actual financial results beat the analysts' financial forecasts?
Based on ClearPoint Neuro's last annual report (Dec 2023), the company's revenue was $23.96M, which missed the average analysts forecast of $24.16M by -0.86%. Apple's EBITDA was $-22.446M, beating the average prediction of $-15.346M by 46.26%. The company's net income was $-22.089M, missing the average estimation of $-22.89M by -3.50%. Apple's SG&A was $24.35M, beating the average forecast of $21.94M by 11.00%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-0.833 by -99.89%. In terms of the last quarterly report (Dec 2023), ClearPoint Neuro's revenue was $6.81M, beating the average analysts' forecast of $6.53M by 4.23%. The company's EBITDA was $-4.282M, beating the average prediction of $-4.149M by 3.20%. ClearPoint Neuro's net income was $-4.619M, missing the average estimation of $-5.585M by -17.30%. The company's SG&A was $6.07M, beating the average forecast of $5.93M by 2.29%. Lastly, the company's EPS was $-0.19, missing the average prediction of $-0.203 by -6.56%